Vaccinex Inc

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in 1997 and is headquartered in Rochester, NY.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in April 2001 and is headquartered in Rochester, NY.

ROCHESTER, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that it will participate in the 10th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021.

Vaccinex to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event

Addition al data from SIGNAL Huntington's disease (HD) trial support continued development in H D and in Alzheimer's disease (AD)

Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update

SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington's disease

CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference

Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference

Live moderated video webcast discussion between members of management and Key Opinion Leader, Eric Siemers, MD on Tuesday, October 27th at 10:00 a.m. EDT Live moderated video webcast discussion between members of management and Key Opinion Leader, Eric Siemers, MD on Tuesday, October 27th at 10:00 a.m. EDT

Vaccinex, Inc. to Present at the Virtual Investor KOL Roundtable

Investors need to pay close attention to Vaccinex (VCNX) stock based on the movements in the options market lately.

Implied Volatility Surging for Vaccinex (VCNX) Stock Options

Shares of micro-cap immunotherapy company Vaccinex Inc (NASDAQ: VCNX) were plunging Tuesday in reaction to an adverse readout.

Vaccinex Plummets After Lead Drug Flunks Midstage Huntingon's Disease Study

Shares of Vaccinex Inc.  tumbled 61.6% in premarket trading on Tuesday after the preclinical biotechnology company said an experimental Huntington's disease treatment, pepinemab, did not meet the primary endpoints in a Phase 2 double-blind, placebo-controlled clinical trial. Earlier this month, Vaccinex had announced plans to study pepinemab in combination with Merck & Co.

Vaccinex's stock falls after investigational drug fails Huntington's disease study

K ey  cognitive endpoint s trending towards but did not reach  statistical  significance in early manifest population . O verall  study does not meet  pre-specified  co- primary endpoints

Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab

ROCHESTER, N.Y., Sept.  17, 2020  (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a novel approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada), through a subsidiary, to evaluate the combination of Vaccinex’s investigational SEMA4D inhibitor, pepinemab, and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in the treatment of patients with advanced, recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

ROCHESTER, N.Y., Aug.  27, 2020  (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease (HD) and cancer, announced the appointment of Robert Scala as Chief Commercial Officer. Robert will build and lead all commercial functions at Vaccinex and provide strategic and functional oversight of commercial operations for the Company starting with pepinemab, potentially the first disease modifying treatment for Huntington’s disease. He will report to Maurice Zauderer, Ph.D., President and CEO, and serve as a member of the Company’s Executive Team.

Vaccinex Announces Appointment of Robert Scala as Chief Commercial Officer

Vaccinex, Inc. (VCNX) delivered earnings and revenue surprises of 23.53% and -100.00%, respectively, for the quarter ended June 2020.

Vaccinex, Inc. (VCNX) Reports Q2 Loss, Misses Revenue Estimates

On track to report potentially pivotal Phase 2 Huntington’s disease topline data by early October

Vaccinex Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Vaccinex, Inc. (VCNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Vaccinex, Inc. (VCNX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Avinger

Bioline RX

Proteostasis Therapeutics

Viveve Medical

Inside the top-ranked stocks that have been exhibiting rising price-to-earnings ratios.

Bet on Rising Price-to-Earnings With 5 Top Stocks

Vaccinex (VCNX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Vaccinex (VCNX) Catches Eye: Stock Jumps 8.1%

Topline data anticipated in October 2020 as previously guided Topline data anticipated in October 2020 as previously guided

Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington’s Disease

Live video moderated discussion with President and CEO, Maurice Zauderer, Ph.D., on Tuesday, June 16, at 10:00 AM ET, immediately followed by an interactive Q&A session

Vaccinex, Inc. to Present at the Virtual Investor Fireside Chat Series

Vaccinex Inc (VCNX) delivered earnings and revenue surprises of 8.16% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Vaccinex Inc (VCNX) Reports Q1 Loss, Lags Revenue Estimates

Approaching key topline data in non-small cell lung cancer and Huntington’s disease

Vaccinex Reports First Quarter 2020 Financial Results and Provides Corporate Update

Data continue to demonstrate durable response in patients as trial nears completion Data continue to demonstrate durable response in patients as trial nears completion

Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting

Vaccinex Inc (VCNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vaccinex Inc (VCNX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Updated data continue to demonstrate a durable clinical benefit in both immunotherapy-naïve patients as well as those previously treated with an immunotherapy regimen Updated data continue to demonstrate a durable clinical benefit in both immunotherapy-naïve patients as well as those previously treated with an immunotherapy regimen

Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting

Presentation highlighted the potential of the company’s lead candidate, the anti-SEMA4D antibody pepinemab, to regulate glial cell activation and neurodegeneration in Alzheimer’s and Huntington’s disease Presentation highlighted the potential of the company’s lead candidate, the anti-SEMA4D antibody pepinemab, to regulate glial cell activation and neurodegeneration in Alzheimer’s and Huntington’s disease

Vaccinex Delivers Virtual Presentation at the Advances in Alzheimer’s and Parkinson’s Therapies  AAT-AD/PD™ Focus Meeting 2020

Key trials in Huntington’s disease and non-small cell lung cancer are near completion; company working with trial sites to assess delays and determine the most efficient path to topline data Key trials in Huntington’s disease and non-small cell lung cancer are near completion; company working with trial sites to assess delays and determine the most efficient path to topline data

News for Vaccinex Inc Stock (VCNX)